验证数据展示
产品信息
60135-2-PBS targets Chromogranin A as part of a matched antibody pair:
MP50241-2: 60135-2-PBS capture and 60135-3-PBS detection (validated in Cytometric bead array)
MP50241-3: 68851-1-PBS capture and 60135-2-PBS detection (validated in Cytometric bead array)
Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
Tested Applications | WB, IHC, IF/ICC, IF-P, Cytometric bead array, Indirect ELISA Application Description |
Tested Reactivity | human, mouse, rat, pig |
Immunogen | Chromogranin A fusion protein Ag0807 种属同源性预测 |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Full Name | chromogranin A (parathyroid secretory protein 1) |
Synonyms | CHGA, CGA, EA-92, Chromogranin-A, AL-11 |
Calculated Molecular Weight | 51 kDa |
Observed Molecular Weight | 50 kDa |
GenBank Accession Number | BC006459 |
Gene Symbol | Chromogranin A |
Gene ID (NCBI) | 1113 |
RRID | AB_2918358 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | P10645 |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. The product is shipped with ice packs. Upon receipt, store it immediately at -80°C |
背景介绍
Chromogranin A is a member of the granin family of neuroendocrine secretory proteins. It is located in secretory vesicles of neurons and endocrine cells. Chromogranin A is the precursor to several functional peptides including vasostatin, pancreastatin, catestatin and parastatin. These peptides negatively modulate the neuroendocrine function of the releasing cell (autocrine) or nearby cells (paracrine). CgA is one of the most used tumor markers in NET's (neuroendocrine tumors) , and elevated CgA concentrations have been demonstrated in serum or plasma of patients with different types of these tumors.